Anti-Human CFH Antibody (SAA0527)

Catalog No.

RHC34601

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

Complement factor H, CFH, H factor 1, HF1, HF, HF2

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P08603

Applications

ELISA, FCM, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0527

Target complement factor H / serum amyloid a signaling in trichloroethylene-induced immune kidney injury., PMID:40373713

Long-Term Outcomes of Anticomplement Factor H Antibody Positive Versus Negative Atypical Hemolytic Uremic Syndrome., PMID:40352901

Long-term GABA supplementation mitigates anxiety by modulating complement and neuroinflammatory pathways., PMID:40274802

Clarifying criteria for complement-mediated TMA in patients without CFH antibodies or complement variants identified., PMID:40254367

Real-world use of complement inhibitors for haemolytic uraemic syndrome: an analysis of the European Rare Kidney Disease Registry cohort., PMID:40224677

The sialome of the retina, alteration in age-related macular degeneration (AMD) pathology and potential impacts on Complement Factor H., PMID:40161805

Glomerular mesangial cells derived complement factor H regulates complement activation, influences cell proliferation, and maintains actin cytoskeleton., PMID:40157080

Common Haplotypes within the Chromosome 1q31.3 Region Determine Systemic Concentrations of the Entire Complement Factor H Protein Family., PMID:40139172

A tumor-binding antibody with cross-reactivity to viral antigens., PMID:40009215

Atypical Hemolytic Uremic Syndrome Associated with BNT162b2 mRNA COVID-19 Vaccine in a Kidney Transplant Recipient: A Case Report and Literature Review., PMID:39997466

Human Factor H and anti-Neisserial surface protein A (NspA) antibodies compete for overlapping binding sites on meningococcal NspA., PMID:39992115

Complement regulators as novel targets for anti-cancer therapy: A comprehensive review., PMID:39826189

Single-Cell Transcriptomics Identifies Selective Lineage-Specific Regulation of Genes in Aortic Smooth Muscle Cells in Mice., PMID:39744838

Identification of plasma proteins binding oxidized phospholipids using pull-down proteomics and OxLDL masking assay., PMID:39566852

SARS-CoV-2 hijacks host CD55, CD59 and factor H to impair antibody-dependent complement-mediated lysis., PMID:39435487

Shiga toxin-producing Escherichia coli infection as a precipitating factor for atypical hemolytic-uremic syndrome., PMID:39347991

The primary systemic vasculitis associated optic neuritis: a retrospective analysis in a single center over 10 years., PMID:39312014

Glomerular injury induced by vinyl carbamate in A/J inbred mice: a novel model of membranoproliferative glomerulonephritis., PMID:39309006

Factor H-related protein 1 in systemic lupus erythematosus., PMID:39136026

Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodies., PMID:39104533

Anti-C5 monoclonal antibody treatment showing pathological resolution of complement-mediated atypical hemolytic uremic syndrome: a case report., PMID:39009967

[Clinical characteristics analysis of 4 cases with acute flaccid myelitis in children]., PMID:38955687

Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators., PMID:38817607

A machine learning-based diagnosis modeling of IgG4 Hashimoto's thyroiditis., PMID:38809347

Genetics in neovascular age-related macular degeneration susceptibility and treatment response to anti-VEGF intravitreal injection: A case series study., PMID:38757252

An unusual case of adult-onset still's disease complicated with anti-complement factor H antibodies associated atypical haemolytic uraemic syndrome., PMID:38745129

Adolescence-onset atypical hemolytic uremic syndrome: is it different from infant-onset?, PMID:38704765

Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn's Disease., PMID:38692557

Managing anti-factor H antibody-associated hemolytic uremic syndrome: time for consensus., PMID:38634874

Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange?, PMID:38632123

Characterization of patients with aHUS and associated triggers or clinical conditions: A Global aHUS Registry analysis., PMID:38604995

Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody., PMID:38558134

Bilateral Retinal Venous Occlusion in Atypical Hemolytic-Uremic Syndrome Due to Complement Factor H Mutation., PMID:38536978

Case report: A family of atypical hemolytic uremic syndrome involving a CFH::CFHR1 fusion gene and CFHR3-1-4-2 gene duplication., PMID:38524137

[Challenges and strategies in the treatment of neovascular age-related macular degeneration]., PMID:38462368

Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways., PMID:38401844

Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy., PMID:38233673

[Comparative characteristics of the complement system in patients with C3-glomerulopathy and atypical hemolytic uremic syndrome of chronic course who suffered an acute episode of thrombotic microangiopathy]., PMID:38158966

Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians., PMID:37990516

Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study., PMID:37984551

Modeling complement activation on human glomerular microvascular endothelial cells., PMID:37954621

Complement factor H Y402H polymorphism results in diminishing CD4+ T cells and increasing C-reactive protein in plasma., PMID:37940659

Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis., PMID:37923132

Eculizumab Versus Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome: A Systematic Review., PMID:37905269

Evaluation of the significance of complement-related genes mutations in atypical postinfectious glomerulonephritis: a pilot study., PMID:37845399

Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?, PMID:37833944

Case report: Autoimmune hemolytic anemia caused by warm and cold autoantibodies with complement activation-etiological and therapeutic issues., PMID:37794962

Atypical hemolytic uremic syndrome: genetically-based insights into pathogenesis through an analysis of the complement regulator CD46., PMID:39949759

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP., PMID:37762692

Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN., PMID:37615951

Document Download

Anti-Human CFH Antibody (SAA0527).pdf